Schrock AB, et al. - Researchers here aim to perform in-depth genomic characterization of a large series of Small-bowel adenocarcinomas (SBAs) and other gastrointestinal tumors to draw comparisons and identify potentially clinically actionable alterations. They recognize that SBA is a molecularly unique intestinal cancer with a relatively high incidence of genomic alterations predictive of response to targeted and immunotherapies.